Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus H R 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus H R 50.
ANDROID 10 vs H.R.-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
12.5 mg orally twice daily
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Category C
Category C
Androgen
Androgen